HUFF-01

Small molecule

HHokkaido University Hospital

HUFF-01 is one of 36 small molecule programs targeting Intracerebral Hemorrhage. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracerebral HemorrhageActive, not recruiting

Intracerebral HemorrhagePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Intracerebral Hemorrhage

#DrugCompanyPhaseTrials

Colcrys

Alnylam Pharmaceuticals

Phase 3

2 2

Activase

Roche

Phase 3

—3

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 4

Statin

Bristol-Myers Squibb

Phase 3

1 5

Olumiant

Eli Lilly

Phase 2

2 6

Crestor

AstraZeneca

Phase 2

2 7

Desferal

Alnylam Pharmaceuticals

Phase 2

2 8

Actos

Takeda

Phase 2

1 9

Tecfidera

Biogen

Phase 2

1 10

Minocycline /d

UUniversity of Florida

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage

Recruiting·HHokkaido University Hospital·Phase 1/2·NCT06361433·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HUFF-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HUFF-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HUFF-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hokkaido University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: HHokkaido University Hospital

HUFF-01

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intracerebral Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News